ストックスクリーナーアプリを入手
44.10
3.55%
1.51
前日終値:
$42.59
開ける：
$42.8
24時間の取引高:
508.17K
Relative Volume:
0.59
時価総額：
$3.15B
収益：
$58.89M
当期純損益:
$-240.88M
株価収益率:
-14.23
EPS:
-3.1
ネットキャッシュフロー:
$-239.96M
1週間 パフォーマンス:
+3.45%
1か月 パフォーマンス:
-3.63%
6か月 パフォーマンス:
+19.80%
1年 パフォーマンス:
-3.82%
1日の値動き範囲:
$42.05
$44.50
1週間の範囲:
$41.49
$44.50
52週間の値動き範囲:
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
名前
Kymera Therapeutics Inc
セクター
電話
857-285-5314
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
KYMR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
44.10 | 3.12B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | 再開されました | B. Riley Securities | Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-06-03 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-05-20 | 再開されました | Stifel | Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-12-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-26 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 開始されました | Oppenheimer | Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 開始されました | Truist | Buy |
| 2023-05-05 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 開始されました | Raymond James | Mkt Perform |
| 2022-08-15 | 開始されました | Jefferies | Buy |
| 2022-08-03 | 開始されました | Goldman | Buy |
| 2022-07-20 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | JP Morgan | Neutral |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2021-09-30 | 開始されました | B. Riley Securities | Neutral |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-09-15 | 開始されました | BofA Securities | Neutral |
| 2020-09-15 | 開始されました | Cowen | Outperform |
| 2020-09-15 | 開始されました | Guggenheim | Buy |
| 2020-09-15 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Kymera Therapeutics Inc (KYMR) 最新ニュース
Kymera Therapeutics Inc. Stock Poised for Technical ComebackQuarterly Trade Report & Accurate Trade Setup Notifications - thegnnews.com
Kymera Therapeutics, Inc. Rings the Opening Bell - Nasdaq
Is Kymera Therapeutics Inc. the Top Chart Pick This WeekWeekly Earnings Recap & Precise Trade Entry Recommendations - kangso.co.kr
Real time social sentiment graph for Kymera Therapeutics Inc.New Guidance & Free Accurate Trade Setup Notifications - Newser
What institutional flow reveals about Kymera Therapeutics Inc.Dividend Hike & Intraday High Probability Alerts - Newser
What indicators show strength in Kymera Therapeutics Inc.2025 Market Sentiment & Smart Investment Allocation Tips - Newser
Sentiment analysis tools applied to Kymera Therapeutics Inc.Weekly Stock Analysis & Weekly Top Gainers Trade List - Newser
What data driven models say about Kymera Therapeutics Inc.’s futureQuarterly Market Summary & Stepwise Entry/Exit Trade Alerts - Newser
Real time breakdown of Kymera Therapeutics Inc. stock performanceGlobal Markets & AI Forecast for Swing Trade Picks - Newser
Smart tools for monitoring Kymera Therapeutics Inc.’s price actionMarket Sentiment Summary & Risk Adjusted Buy/Sell Alerts - Newser
We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely - 富途牛牛
News impact scoring models applied to Kymera Therapeutics Inc.Trade Entry Report & AI Enhanced Trading Alerts - Newser
Can technical indicators confirm Kymera Therapeutics Inc.’s reversalJuly 2025 Intraday Action & Free Weekly Watchlist of Top Performers - Newser
What Fibonacci levels say about Kymera Therapeutics Inc. reboundJuly 2025 Action & Weekly Return Optimization Alerts - Newser
Is Kymera Therapeutics Inc. building a consolidation base2025 Trading Volume Trends & Safe Entry Momentum Stock Tips - Newser
Key resistance and support levels for Kymera Therapeutics Inc.Long Setup & Technical Pattern Alert System - Newser
How liquid is Kymera Therapeutics Inc. stock2025 Geopolitical Influence & AI Enhanced Trade Execution Alerts - kangso.co.kr
Kymera Therapeutics (NASDAQ:KYMR) Downgraded by Wall Street Zen to Sell - Defense World
Analysts Are Updating Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Estimates After Its Second-Quarter Results - Yahoo Finance
Signal strength of Kymera Therapeutics Inc. stock in tech scanners2025 EndofYear Setup & AI Driven Stock Movement Reports - Newser
Is Kymera Therapeutics Inc. stock ready for a breakoutJuly 2025 Breakouts & Long Hold Capital Preservation Plans - Newser
Kymera Therapeutics Inc. Stock Performance After Earnings: Historical InsightsWeekly Stock Summary & Smart Money Movement Alerts - Newser
Kymera Therapeutics’ Earnings Call: Optimism and Strategic Progress - TipRanks
Kymera Therapeutics: Promising Clinical Developments and Strategic Positioning in STAT6 Landscape Justify Buy Rating - TipRanks
Best data tools to analyze Kymera Therapeutics Inc. stockJuly 2025 WrapUp & Free Technical Pattern Based Buy Signals - Newser
Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating - MSN
What makes Kymera Therapeutics Inc. stock price move sharplyInsider Selling & Weekly Top Gainers Trade List - Newser
Leerink Partnrs Issues Optimistic Estimate for KYMR Earnings - Defense World
KYMR Q3 EPS Forecast Lifted by Brookline Capital Management - Defense World
A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $54 to $57 - 富途牛牛
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Q3 Earnings Forecast for KYMR Issued By Leerink Partnrs - Defense World
Kymera Therapeutics Inc. Moves Into Overbought Range Analysts CautiousJuly 2025 Intraday Action & Risk Adjusted Swing Trade Ideas - sundaytimes.kr
Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $59.11 - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2025 Earnings Call Transcript - Insider Monkey
Hatteras Venture Partners Raises Over $200 Million in Capital Across Two Healthcare-Focused Funds - GlobeNewswire Inc.
Kymera Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates - NewsBreak: Local News & Alerts
Kymera Therapeutics: Promising Developments and Strong Financial Position Support Buy Rating - TipRanks
Kymera Therapeutics: Promising Developments in STAT6 Degrader KT-621 Drive Buy Rating - TipRanks
Positive Outlook for Kymera Therapeutics Amid Promising KT-621 Developments and Strong Financial Position - TipRanks
Kymera extends cash runway to 2H 2028 as immunology pipeline advances and collaborations boost funding - MSN
Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Down Following Weak Earnings - Defense World
Kymera Therapeutics Reports Q2 2025 Progress and Partnerships - TipRanks
What analysts say about Kymera Therapeutics Inc. stock outlookHigh Probability Trade Plan with Indicators - Newser
Multi factor analysis applied to Kymera Therapeutics Inc.Earnings Report Summary with Market Impact - Newser
Kymera Therapeutics shares fall 1.14% after-hours after reporting a widened Q2 loss and falling collaboration revenue. - AInvest
Kymera Therapeutics Q2 2025: Unpacking Contradictions in Clinical Expectations, Safety Monitoring, and Dosing Strategies - AInvest
Kymera Therapeutics: Strategic Catalysts and Monetization Potential in a High-Stakes Biotech Landscape - AInvest
Kymera Extends Cash Runway, Boosts Funding through Immunology Pipeline Advancements and Collaborations. - AInvest
Kymera Therapeutics Inc (KYMR) 財務データ
収益
当期純利益
現金流量
EPS
Kymera Therapeutics Inc (KYMR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director |
Jun 30 '25 |
Buy |
44.00 |
655,500 |
28,842,000 |
6,117,295 |
| Ridloff Elena | Director |
Jun 11 '25 |
Option Exercise |
20.29 |
4,500 |
91,305 |
4,500 |
| Ridloff Elena | Director |
Jun 11 '25 |
Sale |
50.00 |
4,500 |
225,000 |
0 |
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):